Researcher | Research Overview
Dr. “Larry” Frelinger is Director of the Center for Platelet Research Studies and Assistant Professor of Pediatrics at Harvard Medical School. Dr. Frelinger received his Ph.D. from Case Western Reserve University and did post-doctoral fellowships in the Department of Neurology at CWRU and at Scripps Clinic and Research Foundation in La Jolla, California. Dr. Frelinger worked in the Biotech industry between 1990 and 1998, first at Biogen and later at Accumetrics where he played important roles in the development of the Verify-Now point-of-care platelet aggregation device and clinical trial leading to its approval. In 1998 Dr. Frelinger re-entered academia, joining the faculty UMass Medical School as Assistant Professor and Associate Director of the Center for Platelet Function Studies, under the mentorship of Dr. Alan Michelson. At UMass, Dr. Frelinger’s research focused on heterogeneity of response to anti-platelet therapy, or what is sometimes termed aspirin resistance or clopidogrel resistance. After coming to BCH in 2009, Dr. Frelinger’s work contributed to guidelines on the use of proton pump inhibitors with clopidogrel, and identified platelet markers associated with VOCs in patients with sickle cell disease and with bleeding severity in pediatric patients with ITP or with severe hemophilia A. Dr. Frelinger’s recent work is focused on the role of platelet subsets, identified by spectral flow cytometry, in health and disease.
Dr. Frelinger is a past Co-Chair of the Platelet Physiology Scientific Subcommittee of the International Society on Thrombosis and Haemostasis and has served as an Editor for Scientific Reports and the journal Platelets. Dr. Frelinger was a contributor to the first three editions of the book Platelets and is Associate Editor of the 4th edition. Dr. Frelinger has published more than 120 peer-reviewed original research articles and is an inventor on three awarded and three provisional U.S. patents.